keyword
MENU ▼
Read by QxMD icon Read
search

Adjuvant chemotherapy and breast cancer

keyword
https://www.readbyqxmd.com/read/29786125/neoadjuvant-chemotherapy-use-in-breast-cancer-is-greatest-in-excellent-responders-triple-negative-and-her2-subtypes
#1
Brittany L Murphy, Courtney N Day, Tanya L Hoskin, Elizabeth B Habermann, Judy C Boughey
BACKGROUND: While breast cancer has historically been treated with surgery followed by adjuvant chemotherapy (AC) and radiation when indicated, neoadjuvant chemotherapy (NAC) use is thought to be increasing; however, the trends of its use in various biological subtypes have not been evaluated. We sought to evaluate the trend of NAC use over time by biological subtype. METHODS: We identified all patients with invasive breast cancer who underwent curative intent surgery and were treated with chemotherapy from 2010 to 2015 from the National Cancer Database...
May 21, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29779938/expression-of-truncated-her2-and-its-prognostic-value-in-her2-positive-breast-cancer-patients
#2
Alaa Mohamed Maria, Mohamed El-Shebiney, Ayman Mohamed El-Saka, Yomna Zamzam
PURPOSE: The purpose of this work was to assess the truncated form of human epidermal growth factor receptor 2 (HER2) such as p95-HER2 expression in HER2-positive breast cancer (BC) patients who developed metastatic disease after adjuvant treatment with a trastuzumab-containing regimen. PATIENTS AND METHODS: Thirty-two histologically diagnosed HER2-positive BC patients who developed distant failure after treatment with trastuzumab-based chemotherapy (CT) regimen as an adjuvant therapy were included in the study...
May 17, 2018: Journal of the Egyptian National Cancer Institute
https://www.readbyqxmd.com/read/29778821/evaluating-mastectomy-skin-flap-necrosis-in-the-extended-breast-reconstruction-risk-assessment-score-for-one-year-prediction-of-prosthetic-reconstruction-outcomes
#3
Nora Hansen, Sasa Espino, Jordan T Blough, Michael M Vu, Neil A Fine, John Ys Kim
BACKGROUND: Rates of mastectomy for breast cancer treatment and immediate reconstruction continue to rise. With increasing scrutiny on outcomes and patient satisfaction, there is an impetus for providers to be more deliberate in deciding appropriate patient selection for breast reconstruction. The Breast Reconstruction Risk Assessment (BRA) Score was developed for prediction of complications after primary prosthetic breast reconstruction, focusing on calculating risk estimations for a variety of complications based on individual patient demographics and perioperative characteristics...
May 17, 2018: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/29778788/maintaining-dose-intensity-of-adjuvant-chemotherapy-in-older-patients-with-breast-cancer
#4
Rahul Ladwa, Timothy Kalas, Shivanshan Pathmanathan, Natasha Woodward, David Wyld, Jasotha Sanmugarajah
INTRODUCTION: Maintaining the relative dose intensity (RDI) of adjuvant chemotherapy at ≥ 85% has been associated with improved treatment outcomes in early-stage breast cancer (ESBC). Increasing evidence has suggested that patients aged ≥ 65 years can maintain the optimal RDI for standard chemotherapy regimens. The present study investigated the RDI of newer adjuvant chemotherapy regimens in this demographic. PATIENTS AND METHODS: We retrospectively analyzed the data from 281 patients aged ≥ 65 years with a diagnosis of ESBC who had received adjuvant chemotherapy across 3 sites in Queensland, Australia from 2010 to 2015...
April 28, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29774315/retrospective-analysis-of-patients-with-synchronous-primary-breast-and-thyroid-carcinoma
#5
İlker Murat Arer, Hakan Yabanoğlu, Murat Kuş, Aydıncan Akdur, Tevfik Avcı
Objective: Breast and thyroid cancers are commonly encountered malignancies. Increased risk of breast cancer in follow-up period of thyroid cancer or vice versa has been reported. However, they have some associations, synchronous presentation of these tumors is rare. We presented 12 patients diagnosed as breast and thyroid cancer and treated at the same time. Materials and Methods: Mastectomy and thyroidectomy were performed in 19 patients at the same time. 7 patients were excluded because of benign thyroid pathology...
April 2018: European Journal of Breast Health
https://www.readbyqxmd.com/read/29773838/impact-of-timing-of-trastuzumab-initiation-on-long-term-outcome-of-patients-with-early-stage-her2-positive-breast-cancer-the-one-thousand-her2-patients-project
#6
Giuseppe Gullo, Naomi Walsh, David Fennelly, Reetesh Bose, Janice Walshe, Dimitrios Tryfonopoulos, Kate O'Mahony, Lisa Hammond, Nuno Silva, Deirdre McDonnell, Josephine Ballot, Cecily Quinn, Enda W McDermott, Denis Evoy, Ruth Prichard, James Geraghty, John Amstrong, John Crown
BACKGROUND: The optimal timing of (neo)adjuvant trastuzumab initiation with respect to chemotherapy and surgery remains undefined. METHODS: Retrospective analysis of a large institutional database of HER2-positive patients who received anti-HER2 therapy. We included all Stage I to III patients treated with trastuzumab with a minimum follow up of 3 years. The date of first breast biopsy was recorded as initial diagnosis. RESULTS: A total of 506 patients [adjuvant: 386 (76%)-neo-adjuvant: 120 (24%)] were included...
May 18, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29770955/laptm4b-gene-copy-number-gain-is-associated-with-inferior-response-to-anthracycline-based-chemotherapy-in-hormone-receptor-negative-breast-carcinomas
#7
Orsolya Rusz, Orsolya Papp, Laura Vízkeleti, Béla Ákos Molnár, Kristóf Csaba Bende, Gábor Lotz, Balázs Ács, Zsuzsanna Kahán, Tamás Székely, Ágnes Báthori, Csilla Szundi, Janina Kulka, Zoltán Szállási, Anna-Mária Tőkés
PURPOSE: To determine the associations between lysosomal-associated transmembrane protein 4b (LAPTM4B) gene copy number and response to different chemotherapy regimens in hormone receptor negative (HR-) primary breast carcinomas. PATIENTS AND METHODS: Two cohorts were analyzed: (1) 69 core biopsies from HR-breast carcinomas treated with neoadjuvant chemotherapy (anthracycline based in 72.5% of patients and non-anthracycline based in 27.5% of patients). (2) Tissue microarray (TMA) of 74 HR-breast carcinomas treated with adjuvant therapy (77...
May 16, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29770779/effect-of-neoadjuvant-chemotherapy-on-the-expression-of-hormone-receptors-and-ki-67-in-chinese-breast-cancer-patients-a-retrospective-study-of-525-patients
#8
Yu-Tuan Wu, Xin Li, Lin-Jie Lu, Lu Gan, Wei Dai, Yan-Ling Shi, Vishnu Prasad Adhikari, Kai-Nan Wu, Ling-Quan Kong
This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and ki67 in Chinese female breast cancer patients. The expression of estrogen receptor (ER), progesterone receptor (PR) and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry (IHC). Differences between specimens made through preoperative core needle biopsy (CB) and excised tissue biopsy (EB) were observed. The positive rates of ER, PR and Ki67 in CB and EB were 65...
November 1, 2017: Journal of Biomedical Research
https://www.readbyqxmd.com/read/29769099/circulating-esr1-mutations-at-the-end-of-aromatase-inhibitor-adjuvant-treatment-and-after-relapse-in-breast-cancer-patients
#9
Violette Allouchery, Ludivine Beaussire, Anne Perdrix, David Sefrioui, Laetitia Augusto, Cécile Guillemet, Nasrin Sarafan-Vasseur, Frédéric Di Fiore, Florian Clatot
BACKGROUND: Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence of circulating ESR1 mutations at the end of adjuvant treatment by AI in early breast cancer had never been clearly established. In this context, the aim of the present study was to evaluate the circulating ESR1 mutation frequency at the end of adjuvant treatment and after relapse. METHODS: This monocentric retrospective study was based on available stored plasmas and included all early breast cancer patients who completed at least 2 years of AI adjuvant treatment and experienced a documented relapse after the end of their treatment...
May 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29768496/the-effect-of-adjuvant-chemotherapy-on-survival-in-korean-patients-with-node-negative-t1c-triple-negative-breast-cancer
#10
Seung Taek Lim, Chan Heun Park, Sung Yong Kim, Seok Jin Nam, Eun Young Kang, Byung-In Moon, Hyouk Jin Lee, Ye Won Jeon, Hongki Gwak, Young Jin Suh
BACKGROUND: The present study investigated the prognostic role of adjuvant systemic chemotherapy in patients with node negative, T1c triple negative breast cancer (TNBC) from a nationwide cohort. In addition, the prognostic effect between 3 different chemotherapy regimens were compared in node-negative T1c TNBC patients by subgroup analysis. METHODS: From the Korean breast cancer registry database, 1,151 T1c node negative TNBC patients were included in this study...
2018: PloS One
https://www.readbyqxmd.com/read/29768327/survival-benefit-of-neoadjuvant-chemotherapy-for-resectable-breast-cancer-a-meta-analysis
#11
Yan Chen, Xiu-E Shi, Jin-Hui Tian, Xu-Juan Yang, Yong-Feng Wang, Ke-Hu Yang
BACKGROUND: Neoadjuvant chemotherapy (NAC) increases breast conservation rates in patients with resectable breast cancer at the associated cost of higher locoregional recurrence rates; however, the magnitude of the survival benefits of NAC for these patients remains undefined. Therefore, we aimed to clarify the survival benefit of NAC versus postoperative chemotherapy by conducting an updated meta-analysis of randomized clinical trials (RCTs). METHODS: The authors searched the Cochrane Library, PubMed, Embase, Web of Science, Chinese biomedical literature database, and Chinese Scientific Journals full-text database from their inception to December 2016...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29766456/prognostic-role-for-the-derived-neutrophil-to-lymphocyte-ratio-in-early-breast-cancer-a-geicam-9906-substudy
#12
A J Templeton, Á Rodríguez-Lescure, A Ruíz, E Alba, L Calvo, M Ruíz-Borrego, A Santaballa, C A Rodríguez, C Crespo, M Ramos, J M Gracia-Marco, A Lluch, I Álvarez, M I Casas, M Sánchez-Aragó, R Caballero, E Carrasco, E Amir, M Martin, A Ocaña
PURPOSE: Elevated markers of host inflammation, a hallmark of cancer, have been associated with worse outcomes in several solid tumors. Here, we explore the prognostic role of the derived neutrophil-to-lymphocyte ratio (dNLR), across different tumor subtypes, in patients with early breast cancer. PATIENTS AND METHODS: This was a retrospective analysis of 1246 patients with lymph node-positive, operable early breast cancer enrolled in the GEICAM/9906 trial, a multicenter randomized phase 3 study evaluating adjuvant chemotherapy...
May 15, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29766362/exploration-of-tumour-infiltrating-lymphocytes-as-a-predictive-biomarker-for-adjuvant-endocrine-therapy-in-early-breast-cancer
#13
Erik J Blok, Charla C Engels, Geeske Dekker-Ensink, Elma Meershoek-Klein Kranenbarg, Hein Putter, Vincent T H B M Smit, Gerrit-Jan Liefers, James P Morden, Judith M Bliss, R Charles Coombes, John M S Bartlett, Judith R Kroep, Cornelis J H van de Velde, Peter J K Kuppen
PURPOSE: Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic for disease-free survival and predictive for the benefit of chemotherapy in patients with early breast cancer, but have not been studied for endocrine therapy. EXPERIMENTAL DESIGN: The number of CD8-positive TILs was assessed in a subcohort of 236 patients in the Intergroup Exemestane Study. AQ After 2-3 years of adjuvant tamoxifen, AQpatients were randomized between the schemes of continuation for 5 years on tamoxifen and switching to exemestane...
May 15, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29761323/effect-of-glucocorticoid-use-on-survival-in-patients-with-stage-i-iii-breast-cancer
#14
Ching-Hung Lin, Po-Ya Chuang, San-Lin You, Chun-Ju Chiang, Chiun-Sheng Huang, Ming-Yang Wang, Ming Chao, Yen-Shen Lu, Ann-Lii Cheng, Chao-Hsiun Tang
PURPOSE: Glucocorticoids (GCs) are commonly used in breast cancer patients to ameliorate emesis induced by chemotherapy. Some preclinical studies have suggested that systemic GCs might promote survival of estrogen receptor (ER)-negative breast cancer cells. This study aims to clarify their clinical effect on patient survival. METHODS: A total of 18,596 women with newly diagnosed stage I-III breast cancer in 2002-2006 were identified from the Taiwan Cancer Database and drug treatment was examined from the Taiwan National Health Insurance Claims Database...
May 14, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29757069/accuracy-of-a-single-measurement-site-for-self-monitoring-of-patients-with-breast-cancer-at-risk-for-lymphedema
#15
Janine T Hidding, Carien H G Beurskens, Marijke T De Vries, Maria W G Nijhuis-van der Sanden, Hanneke W M van Laarhoven, Philip J van der Wees
PURPOSE: Early detection of breast cancer-related lymphedema through simple self-monitoring techniques may lead to early treatment and improved outcomes. METHODS: Prospective study of circumference measurements at four time points before, during, and after adjuvant chemotherapy with docetaxel, doxorubicin, and cyclophosphamide. Volume was calculated using the 10-cm interval circumference measurement method (reference test) and percentage difference between arms, for volume and circumference, was determined...
May 14, 2018: Physiotherapy Theory and Practice
https://www.readbyqxmd.com/read/29753866/characterization-of-phenolic-extracts-from-brava-extra-virgin-olive-oils-and-their-cytotoxic-effects-on-mcf-7-breast-cancer-cells
#16
Patricia Reboredo-Rodríguez, Carmen González-Barreiro, Beatriz Cancho-Grande, Tamara Y Forbes-Hernández, Massimiliano Gasparrini, Sadia Afrin, Danila Cianciosi, Alegría Carrasco-Pancorbo, Jesús Simal-Gándara, Francesca Giampieri, Maurizio Battino
The aim of the present work was to evaluate the phenolic profile of the 'Brava' extra virgin olive oil and assess its potential as a "natural adjuvant" in combination with chemotherapy treatment. The total phenol content of the phenolic extracts was 764 mg gallic acid equivalents/kg and the total antioxidant capacity was 2309, 1881 and 2088 μM trolox equivalents/kg determined by Diphenyl-1-picrylhydrazyl free radical method, Ferric Reducing Antioxidant Power and Trolox Equivalent Antioxidant Capacity assay, respectively...
May 10, 2018: Food and Chemical Toxicology
https://www.readbyqxmd.com/read/29745076/ten-years-of-using-adjuvant-trastuzumab-in-breast-cancer-in-serbia-single-institution-experience
#17
Ana Cvetanovic, Sladjana Filipovic, Nikola Zivkovic, Lazar Popovic, Milos Kostic, Miodrag Djordjevic, Aleksandar Karanikolic, Dane Krtinic
PURPOSE: The purpose of this study was to determinate disease-free interval (DFI) and overall survival (OS) in HER2-positive breast cancer patients who received adjuvant trastuzumab at the University Clinic of Nis, Serbia, and to investigate the influence of clinicopathological and biological characteristics of the tumor on prognosis. The second aim was to determinate the most frequent cause for the treatment discontinuation, recurrence rate, as well as the site of most common localization of the first recurrence of disease...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29744328/bilateral-metachronous-breast-carcinoma-a-rare-case-report
#18
Anand Singla, Navneet Kaur, Darshanjeet Singh Walia, Deeksha Singla
The occurrence of bilateral breast cancer is rare. A second primary in the contralateral breast can either be synchronous or metachronous. Lobular carcinoma of the breast is known for its multicentricity and bilateral spread. The synchronous mixed pattern of carcinoma of the breast has also been reported in the same breast. The family history of breast carcinoma, estrogen receptor negativity, and human epidermal growth factor receptor-2 positivity are risk factors for the development of contralateral breast malignancy...
April 2018: International Journal of Applied and Basic Medical Research
https://www.readbyqxmd.com/read/29737474/incidence-and-risk-factors-for-congestive-heart-failure-in-patients-with-early-breast-cancer-who-received-anthracycline-and-or-trastuzumab-a-big-data-analysis-of-the-korean-health-insurance-review-and-assessment-service-database
#19
Jung Yoon Choi, Eun Young Cho, Yoon Ji Choi, Jeong Hyeon Lee, Seung Pil Jung, Kyu Ran Cho, Chul Yong Kim, Yeul Hong Kim, Kyong Hwa Park
PURPOSE: We aimed to analyze the incidence, time to occurrence, and congestive heart failure (CHF) risk factors for early breast cancer patients treated with anthracycline (AC)-based chemotherapy and/or trastuzumab (T) therapy in Korea. METHODS: We included female patients > 19 years old from the Health Insurance Review and Assessment Service database who had no prior CHF history and had been diagnosed with early breast cancer between January 2007 and October 2016...
May 8, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29732352/pegfilgrastim-for-primary-prophylaxis-of-febrile-neutropenia-in-breast-cancer-patients-undergoing-tac-chemotherapy
#20
Jihyoun Lee, Jong Eun Lee, Zisun Kim, Sun Wook Han, Sung Mo Hur, Sung Yong Kim, Min Hyuk Lee, Cheol Wan Lim
Purpose: Primary prophylaxis with granulocyte colony-stimulating factor can effectively prevent febrile neutropenia (FN) during breast cancer treatment. The aims of this study were to evaluate the incidence of FN and the ANC profile in patients undergoing chemotherapy and pegfilgrastim primary prophylaxis. Methods: Patients receiving 6 cycles of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy were included in this study. Pegfilgrastim was administered with analgesics 24 hours after treatment...
May 2018: Annals of Surgical Treatment and Research
keyword
keyword
31152
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"